Paloma Giangrande

Company: Wave Life Sciences

Job title: Vice President, Platform Discovery Sciences, Biology

Seminars:

AIMers: Correcting Driver Mutations for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) and Beyond 11:30 am

Understand how our RNA editing platform allows for correction of driver mutations of AATD Developing RNA Editing AIMers to correct homozygous “ZZ” mutations back to “MZ” heterozygous state AIMers lead to durable and functional expression of M-AAT protein, establishing an RNA editing platform to target liver and potentially other organsRead more

day: Day Two